Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...